ClinicalTrials.gg
RecruitingNCT07820813IDUNNUpdated Nov 16, 2026

bNAbs and Anti-PD-1 in HIV

A Phase 2 interventional study of 3BNC117-LS and 10-1074-LS in HIV-1, sponsored by Ole Schmeltz Søgaard. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Ole Schmeltz Søgaard · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 16, 2026Now RecruitingFirst site in Denmark+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Antiretroviral therapy (ART) has significantly extended the life expectancy of people living with HIV-1 (PLWH), but it does not cure the infection. Broadly neutralizing antibodies (bNAbs), such as 3BNC117 and 10-1074, not only neutralize circulating virus but also engage the immune system to enhance HIV-1-specific CD8+ T cell responses and stimulate autologous neutralizing antibody production. In some individuals who discontinue ART, bNAb treatment resulted in long-term post-treatment control. However, a major obstacle to immunotherapeutic strategies in PLWH is the immune dysfunction that persists despite long-term suppressive ART. One contributing factor is the immune checkpoint receptor programmed death-1 (PD-1), which is expressed on T cells and suppresses their function when engaged by its ligands. Blocking PD-1 with monoclonal antibodies (mAbs) can reverse T cell exhaustion, a strategy that has resulted in extraordinary increases in survival and cure in cancer treatment and in ex vivo and animal studies of HIV. These findings support the rationale for incorporating PD-1 inhibition in HIV cure strategies. Low-dose nivolumab, an anti-PD-1 mAb, has been shown to be safe in clinical trials. The hypothesis is that combining a single low-dose of nivolumab with long-acting bNAbs (3BNC117-LS and 10-1074-LS) during an analytical treatment interruption (ATI) will reduce T cell exhaustion and boost HIV-1-specific immune responses, as a novel strategy to induce sustained virological control without ART even after the bNAbs have been cleared from the body.

02

Conditions studied

  • HIV-1

Keywords

  • HIV-1
  • IDUNN
  • bNAbs
  • 3BNC117-LS
  • 10-1074-LS
  • anti-PD-1
  • nivolumab
03

In context

Lead sponsor

This is the only study on the registry with Ole Schmeltz Søgaard as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability and willingness to provide
  • sAg or HBV DNA as well as Ag or HCV RNA negative or anti-core antibody negative
  • Current >500 cells/μL (at screening)
  • Plasma -1 RNA \<50 copies/mL by standard assays for at least 15 months (a single measurement >50 but \<500 copies/mL during this time period is allowable)
  • On integrase inhibitor (INSTI) or boosted protease inhibitor (PI) based regimen at time of randomization, if previously on non-nucleoside reverse transcriptase inhibitor (NNRTI) has switched at least 4 weeks prior to randomization
  • Females of (i.e., participants who have not been for at least 24 consecutive months, who have had menses within the preceding 24 months, or who have not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy), negative serum or urine pregnancy test monthly
  • Pregnancy prevention (heterosexual contact(s)):

    o Females must agree to use highly eWective methods: Hormonal contraception, intrauterine device, or intrauterine hormone-releasing system from at least 2 weeks before the bNAb infusion and for entire trial period of 60 weeks and 15 months following the bNAb infusion

  • Transmission prevention

    • Participants must agree to use barrier prevention during ART interruption and until plasma HIV-1 RNA levels are resuppressed again following ART re-start
    • Partners of study participants should be willing to receive counselling on the need for PrEP according to national recommendations

Exclusion criteria

Exclusion Criteria:

  • Current, or history of:
  • cardiovascular disease (e.g., cardiac insuWiciency, coronary artery disease, cardiomyopathy, congestive heart failure, family history of congenital long syndrome, family history of sudden death)
  • , excluding non-melanoma skin cancers
  • Solid organ transplant
  • or antibody-mediated diseases (including not limited to type 1 diabetes mellitus, inflammatory bowel diseases, scleroderma, severe psoriasis, myocarditis, uveitis, pneumonitis, systemic lupus erythematosus, rheumatoid arthritis, optic neuritis, myasthenia gravis, adrenal insuWiciency, hypothyroidism and/or hyperthyroidism, autoimmune thyroiditis, sarcoidosis, and vitiligo)
  • Known to the components of 3BNC117-LS, 10-1074-LS or nivolumab or their analogues
  • -1 reservoir predicted resistant to neutralization by 10-1074 using genotypic analysis (as defined in section 11.3.2.9)
  • Known HIV-1 subtype CRF01-AE due to resistance to 10-1074-LS
  • Receipt of strong or systemic chemotherapeutic agents within 28 days prior to screening
  • Laboratory abnormalities in the parameters listed below:
  • Estimated (eGFR) \<60 mL/min
  • or ALT >x1.25 (ULN)
  • Positive Quantiferon test
  • TPO antibodies >35 IU/mL
  • >1.25 ULN
  • Pregnancy or lactation
  • Any vaccination 2 weeks prior to baseline
  • Any significant acute infection (e.g. influenza, COVID-19) or any other clinically significant illness 2 weeks prior to screening
  • Have received a long-acting ART regimen within the last 12 months (e.g. cabotegravir or lenacaprivir containing regimen)
  • Known resistance to >2 classes of ART
  • Participation in other interventional trial
  • Any other conditions, which in the opinion of the investigator would make the participant unsuitable for inclusion, or could interfere with the participants participating in or completion of the study
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    A: bNAbs/anti-PD-1a

    3BNC117-LS, 10-1074-LS and nivolumab

    Drug: 3BNC117-LS · Drug: 10-1074-LS · Drug: Nivolumab

  • Active comparator
    B: bNAbs/placebo

    3BNC117-LS, 10-1074-LS and placebo

    Drug: 3BNC117-LS · Drug: 10-1074-LS · Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time from the day of stopping ART to the day of meeting criteria for loss of immunological control of HIV-1 (defined below)

    Loss of immunological control of HIV-1 is defined as one or more of the following three criteria: * Six weeks of consecutive plasma HIV-1 RNA \>1,000 copies/mL or confirmed \>100,000 copies/mL * Confirmed (on two consecutive measurements) CD4+ T cell count \<350 cells/mm3 * Participant's request or if the ATI in the opinion of the Sponsor or Investigator poses an unacceptable risk to the participant

    Time frame: 60 weeks

Secondary outcomes

  1. The safety and tolerability of the Investigational Medicinal Products (IMPs)

    Frequency and severity of adverse events (AEs), serious AEs (SAEs). Relationship to study drug and severity will be graded according to Division of AIDS (DAIDS) Grading Table, v2.1

    Time frame: Adverse events will be recorded from signing of the informed consent form and until end of study week 60 or visit 50 following restart of ART, whichever comes first.

  2. The frequency of post-interventional immunological control of HIV-1

    Durable immunological control of HIV-1 as defined in the primary outcome

    Time frame: At week 24, 36, 48 and 60

  3. The effect of the IMPs on HIV-1-specific T cells responses before, during and after the ATI

    Changes in HIV-1-specific T cell responses as measured by flow cytometry, T cell Elispot, and lymphocyte proliferation.

    Time frame: From baseline to weeks 8, 12, 16, 24 and 60 or ART-restart, whichever comes first

  4. The effect of the IMPs on the intact HIV-1 reservoir before, during and after the ATI

    Changes in the levels of intact proviral HIV-1 DNA per million CD4+ T cells as measured by PCR-based techniques

    Time frame: From baseline to weeks 24 and 60 or ART-restart, whichever comes first

  5. The effect of the IMPs on the immune cell phenotype, activation and exhaustion

    Changes in the distribution of immune cell subsets, activation and exhaustion markers as measured by flow cytometry

    Time frame: From baseline to weeks 8, 16, 24 and 60 or ART-restart, whichever comes first

  6. The effect of autologous antibodies on post-interventional immunological control of HIV-1

    Changes in autologous neutralizing antibody titers from baseline as determined by ex vivo neutralization assays

    Time frame: Time from the day of stopping ART to weeks 24 and 60 or day of restarting ART, whichever comes first

  7. bNAb sensitivity

    Proviral DNA/plasma virus bNAb sensitivity by genotypic or phenotypic analyses

    Time frame: Baseline and time of ART re-initiation (visit 30) during the 60 weeks of ATI

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Sep 2029, 35 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Sep 15, 2026
StartActual
Oct 7, 2026was Sep 2026
Primary completionEst.
Sep 15, 2029
CompletionEst.
Sep 15, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
1 site added — first site in Denmark
Show site
  • Aarhus University Hospital · Aarhus, Denmark
Nov 16, 2026
Start date
Sep 15, 2026→Oct 7, 2026 (actual)
Nov 16, 2026
Sponsor
Collaborators added: Copenhagen University Hospital, Rigshospitalet; collaborators removed: Monash University·Rigshospitalet, Denmark·Royal Prince Alfred Hospital, Sydney, Australia
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Denmark
    Show site
    • Aarhus University Hospital · Aarhus, Denmark
    Start date Sep 15, 2026→Oct 7, 2026 (now actual)
    Sponsor Collaborators added: Copenhagen University Hospital, Rigshospitalet; collaborators removed: Monash University·Rigshospitalet, Denmark·Royal Prince Alfred Hospital, Sydney, Australia
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07820813
Lead sponsor
Ole Schmeltz Søgaard
Collaborators
Aalborg University Hospital, Gødstrup Hospital, Odense University Hospital, Hvidovre University Hospital, Copenhagen University Hospital, Rigshospitalet, Oslo University Hospital, Karolinska University Hospital, Landspitali University Hospital
Responsible party
Ole Schmeltz Søgaard (Professor, University of Aarhus) — Sponsor-investigator
First posted
Sep 15, 2026
Start date
Oct 7, 2026
Primary completion
Sep 15, 2029 (estimated)
Completion
Sep 15, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Ole S Søgaard, Professor
Contact
olesoega@rm.dk
Jesper D Gunst, Ass. professor
study chair · Aarhus University; Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion